There has not been a “first” ONCX R/S and there is no need for one with an O/S of just 110,000,000.
Uhh…You mean $20,000,000 in non-dilutive grants from foundations and the US government like her other company?
That would be great.
Wrong. ONCX has sufficient funding to see the company through until results from the second dosing results are reported.
Wrong. Results from the first group are available in multiple filings which is why the FDA is allowing the second dosing group.
Wrong. ONCX was created by Greenville Health System for the purpose of potentially advancing a Cancer treatment into commercial markets.
GHS is 501c3 charitable health care provider and medical research facility, with multiple campuses, roughly 15,000 employees and over 100 years of service to their communities.
Lets not forget early grants from the Susan G. Komen foundation, the US government and accredited investment from folks like Earnest Mario, the former CEO of Glaxo NYSE: GSK.
I say it all the time.
The only thing more fun than making money is having an audience.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.